NCT05305131View on ClinicalTrials.gov

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2026

Conditions
Nasopharyngeal Cancer
Interventions
DRUG

cisplatin and gemcitabine

Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2

DRUG

induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.

Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes

Trial Locations (1)

Unknown

RECRUITING

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER